Howard L. Elford

Molecules for Health (United States) — United States

Chemistry · Physical Sciences

28h-index2.9kcitations125works4.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Metal-Catalyzed Oxygenation Mechanisms(53), Metal complexes synthesis and properties(37), Estrogen and related hormone effects(22), HIV/AIDS drug development and treatment(10), Cancer-related Molecular Pathways(10)

Publications125 total

Targeting the Cell Cycle, RRM2 and NF-κB for the Treatment of Breast Cancers
Cancers·2024· 4 citedOpen Access
Abstract 5989: Targeting RRM2 & cell cycle for breast cancer treatment
Cancer Research·2023· 1 cited
Supplementary Figure S6 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
2023Open Access
Figure S2 from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure S2 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
2023Open Access
Supplementary Table S1 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
2023Open Access
Figure S1 from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
2023Open Access
Supplementary Figure S4 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
2023Open Access
Supplementary Figure S1 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
2023Open Access
Supplementary Methods from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
2023Open Access
Figure S3 from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
2023Open Access
Data from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
2023Open Access
Supplementary Figure S4 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
2023Open Access
Supplementary Methods from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
2023Open Access
Figure S3 from Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer
2023Open Access
Data from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
2023Open Access
Supplementary Figure S5 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
2023Open Access
Supplementary Figure S3 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
2023Open Access
Supplementary Figure Legends and Methods from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
2023Open Access
Supplementary Figure Legends and Methods from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Thomas Szekeres(10), Monika Fritzer‐Szekeres(7), Vincent S. Gallicchio(7), Bart van’t Riet(6), Michael Grusch(5), Georg Krupitza(5), Mohammed S Inayat(5), Christopher N. Mayhew(4), Galen L. Wampler(3), Jonathan D. Phillips(3), A Vachálková(3), Leon A. Saryan(2), Else Ankel(2), Chitra Krishnamurti(2), David H. Petering(2), Zsuzsanna Bagó-Horváth(2), Mansoor Ahmed(2), Richard E. Loughlin(2), John M. Buchanan(2), Monika Fritzer(2)